Vivoryon Therapeutics N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
13 sep 2016 - 07:00
Statutaire naam
Vivoryon Therapeutics N.V.
Titel
Combination therapy with Glutaminyl Cyclase (QC) inhibitor PQ912 & pGlu-Abeta specific antibody PBD-C06 shows clear additive effects in reducing pGlu-Abeta as well as Abeta in Alzheimer-mouse model
Bericht
Combination therapy with Glutaminyl Cyclase (QC) inhibitor PQ912 and pGlu-Abeta specific antibody PBD-C06 shows clear additive effects in reducing pGlu-Abeta as well as Abeta in Alzheimer-mouse model
HALLE(SAALE), Germany, 13 September 2016 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announced today first results of a preclinical combination trial targeting pGlu-Abeta.
An additive effect on lowering pGlu-Abeta (pyroglutamate-Abeta) as well as total Abeta was observed with a double-pronged approach of targeting toxic pGlu-Abeta by combining the Glutaminyl Cyclase-inhibitor PQ912 to block pGlu-Abeta formation and the mouse version of the pGlu-Abeta specific antibody, PBD-C06, to increase clearance in an AD animal model.
Gerelateerde downloads
Datum laatste update: 01 september 2024